NCT00421928View on ClinicalTrials.gov

Tapentadol (CG5503)

PHASE3CompletedINTERVENTIONAL

Enrollment

1,030

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

December 31, 2008

Conditions

Osteoarthritis, KneePain

Interventions

DRUG

oxycodone

10, 20, 30, 40, 50mg twice a day (BID) during 15 weeks

DRUG

placebo

matching placebo twice a day (BID) during 15 weeks

DRUG

tapentadol (CG5503)

50, 100, 150, 200, 250mg twice a day (BID) during 15 weeks

Sponsors

Collaborators (1)

Grünenthal GmbH

All Listed Sponsors

collaborator

Grünenthal GmbH

INDUSTRY

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY